Form 4: Gilead Sciences Chief Commercial Officer Exercises Options and Sells Shares Under Pre-Arranged Trading Plan

Gilead Sciences' Chief Commercial Officer, Johanna Mercier, executed a series of transactions on May 22, 2025, involving the exercise of stock options and subsequent sale of common stock, all conducted under a pre-established Rule 10b5-1 trading plan.

Summary

• Johanna Mercier, Chief Commercial Officer of Gilead Sciences, Inc. (GILD), engaged in multiple stock transactions on May 22, 2025.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on February 20, 2025.
• Mercier exercised non-qualified stock options to acquire a total of 25,000 shares of common stock at an exercise price of $66.64 per share.
• Concurrently, she sold a total of 28,000 shares of common stock.
• The sales occurred at weighted average prices of approximately $107.5169 for 12,500 shares, $107.5231 for another 12,500 shares, and $107.5212 for 3,000 shares.
• Following these transactions, Johanna Mercier's direct beneficial ownership of Gilead Sciences common stock is 121,152 shares.
• The options exercised were part of a grant with a four-year vesting schedule, where 25% vested on the first anniversary of the grant date, and the remainder vests quarterly at 6.25%.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there's insider selling, it's under a pre-arranged 10b5-1 plan, which is a common and expected practice for executives to manage their equity compensation and liquidity. The exercise of options at a lower price and sale at a higher market price indicates a profitable and planned transaction for the individual, not necessarily a negative signal for the company.

Positives

• The exercise of stock options at a lower price ($66.64) and subsequent sale at a significantly higher market price (around $107.50) indicates a profitable transaction for the insider.
• The transactions were conducted under a Rule 10b5-1 trading plan, which suggests a pre-planned and orderly disposition of shares, reducing concerns about opportunistic insider selling.

Negatives

• The sale of 28,000 shares by a Chief Commercial Officer could be perceived by some investors as a reduction in insider exposure, although the pre-planned nature mitigates this.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• Johanna Mercier, Chief Commercial Officer, engaged in the exercise of stock options and subsequent sale of common stock of Gilead Sciences, Inc., which are transactions between an executive and the company/its stock.

Stakeholder Impact

• Shareholders: The sale of shares by a C-level executive could be viewed with slight caution, but the 10b5-1 plan mitigates concerns about opportunistic selling. The transactions represent a routine part of executive compensation and liquidity management.

Key Dates

Recommendation

Keywords

Gilead Sciences, GILD, SEC Form 4, Insider Trading, Stock Option Exercise, Stock Sale, Rule 10b5-1 Plan, Johanna Mercier, Chief Commercial Officer, Biopharmaceutical, Pharmaceuticals